- Home
- NCPL vs BCAB Comparison
NCPL vs BCAB Comparison
Compare NCPL & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NCPL | BCAB |
|---|---|---|
| Founded | 1984 | 2007 |
| Country | United States | United States |
| Employees | 20 | N/A |
| Industry | Investment Managers | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.1M | 6.4M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | NCPL | BCAB |
|---|---|---|
| Price | $0.56 | $3.67 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 647.1K | 48.4K |
| Earning Date | 03-19-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.86 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $300,000.00 |
| Revenue This Year | $739.37 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.31 | $0.12 |
| 52 Week High | $8.75 | $6.52 |
Technical Indicators
Market Signals| Indicator | NCPL | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 42.42 | 48.67 |
| Support Level | $0.35 | $3.24 |
| Resistance Level | $0.60 | $6.33 |
| Average True Range (ATR) | 0.09 | 0.37 |
| MACD | -0.05 | 0.02 |
| Stochastic Oscillator | 13.95 | 45.46 |
Price Performance
Historical ComparisonAbout NCPL Netcapital Inc.
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.